Eli Lilly CEO says the company sees ‘significant common cause’ with Trump administration
Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there were reasons for concern.
Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised guidance,
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and Zepbound. The 2025 outlook forecasts up to $61 billion.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results for its obesity therapy tirzepatide fell short of Street forecasts. Novo Nordisk (NVO),
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.
pharmaphorum22h
Lilly trims sales forecast on weaker obesity/diabetes growth
Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...
FiercePharma1d
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 ...
Ibj.com2d
Lilly shares fall midday on lower fourth quarter revenue guidance
Shares of Eli Lilly and Co. fell more than 7% in midday trading Tuesday after the Indianapolis company announced its fourth ...
Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25
Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...
Lilly blames slower-than-expected growth for 2024 sales miss
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...